Ceftriaxone monotherapy for the treatment of febrile neutropenia in patients with solid tumors: a prospective study of 100 episodes.

Author: Benard-ThieryIsabelle, ChamoreyEmmanuel, FoaCyril, LargillierRémy, MagneNicolas, OttoJosiane, ThyssAntoine, ViotMichèle

Paper Details 
Original Abstract of the Article :
BACKGROUND: Broad-spectrum beta-lactam is the standard therapy for febrile neutropenia (FN) in cancer patients. The aim of our study was to evaluate the treatment of FN by a once-daily administration of ceftriaxone (CFX) alone. MATERIAL/METHODS: From Jan. 1, 1997 to Dec. 31, 2001 we prospectively a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/15507863

データ提供:米国国立医学図書館(NLM)

Ceftriaxone Monotherapy for Febrile Neutropenia

This research explores the treatment of febrile neutropenia (FN), a condition where a low neutrophil count leads to fever, in patients with solid tumors. The study aimed to evaluate the effectiveness of a once-daily administration of ceftriaxone (CFX) alone. The researchers used a prospective study design, analyzing 100 episodes of FN in 94 patients. Their findings revealed that CFX monotherapy led to a successful response in 87% of cases. This success rate varied based on the cause of fever: FUO (92%), CDI (83.3%), and MDI (68.4%). Notably, treatment success was significantly lower in patients with a performance status (PS) of 2 or higher.

The Advantages of CFX Monotherapy

This study demonstrates the significant benefits of using CFX monotherapy for treating FN in patients with solid tumors. The study showed that CFX monotherapy is effective in a majority of cases, with a success rate exceeding 80%. This is especially remarkable given that FN is a serious condition that can lead to life-threatening infections. The effectiveness of CFX, coupled with its low cost and easy administration, makes it a valuable option for managing FN in patients with solid tumors.

Ceftriaxone: A Practical and Effective Treatment Option

Imagine a desert oasis where a single, well-placed palm tree can provide shade and sustenance. That’s what ceftriaxone is like for patients with FN – a simple yet effective solution. The study highlights the practical advantages of CFX monotherapy: it’s well-tolerated, easy to administer, affordable, and highly effective. This makes it a valuable tool for clinicians treating patients with solid tumors who are battling FN.

Dr.Camel's Conclusion

This research provides evidence that a single-agent regimen of ceftriaxone can be an effective treatment option for febrile neutropenia in patients with solid tumors. Ceftriaxone’s ease of use and effectiveness make it a valuable resource for healthcare professionals treating these patients. It's a testament to the fact that sometimes simple solutions are the best.

Date :
  1. Date Completed 2005-01-13
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

15507863

DOI: Digital Object Identifier

4719

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.